CL2022000202A1 - Composiciones de oligonucleótidos y métodos para realizarlas (divisional de la solicitud no. 201602749) - Google Patents
Composiciones de oligonucleótidos y métodos para realizarlas (divisional de la solicitud no. 201602749)Info
- Publication number
- CL2022000202A1 CL2022000202A1 CL2022000202A CL2022000202A CL2022000202A1 CL 2022000202 A1 CL2022000202 A1 CL 2022000202A1 CL 2022000202 A CL2022000202 A CL 2022000202A CL 2022000202 A CL2022000202 A CL 2022000202A CL 2022000202 A1 CL2022000202 A1 CL 2022000202A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- making
- divisional application
- oligonucleotide compositions
- oligonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Método de fase sólida para realizar oligonucleótidos mediante ciclos de acoplamiento secuenciales que incluyen al menos un acoplamiento de una subunidad de dímero de dinucleótido con un grupo de extremo 3' libre de una cadena en crecimiento. Las composiciones producidas por dichos métodos pueden incluir una cantidad reducida de uno o más productos de oligonucléotido (N-x). Composiciones farmacéuticas que incluyen dichas composiciones de oligonucleótido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987396P | 2014-05-01 | 2014-05-01 | |
US201562151909P | 2015-04-23 | 2015-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000202A1 true CL2022000202A1 (es) | 2023-02-10 |
Family
ID=54359301
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016002749A CL2016002749A1 (es) | 2014-05-01 | 2016-10-28 | Una composición reducida en impurezas n-1 que comprende un compuesto de polinucleótido unido por enlaces inter-subunidad de fosforamidato n3-p5 o una sal farmacéuticamente aceptable del mismo y su método de síntesis en base a dímeros de amino-dinucleótido fosforamidato-5-fosforamidita-3 protegido. |
CL2018001212A CL2018001212A1 (es) | 2014-05-01 | 2018-05-04 | Composiciones de oligonucleótidos y métodos para realizarlas (divisional de sol. n°2749-16) |
CL2018001213A CL2018001213A1 (es) | 2014-05-01 | 2018-05-04 | Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16) |
CL2022000202A CL2022000202A1 (es) | 2014-05-01 | 2022-01-26 | Composiciones de oligonucleótidos y métodos para realizarlas (divisional de la solicitud no. 201602749) |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016002749A CL2016002749A1 (es) | 2014-05-01 | 2016-10-28 | Una composición reducida en impurezas n-1 que comprende un compuesto de polinucleótido unido por enlaces inter-subunidad de fosforamidato n3-p5 o una sal farmacéuticamente aceptable del mismo y su método de síntesis en base a dímeros de amino-dinucleótido fosforamidato-5-fosforamidita-3 protegido. |
CL2018001212A CL2018001212A1 (es) | 2014-05-01 | 2018-05-04 | Composiciones de oligonucleótidos y métodos para realizarlas (divisional de sol. n°2749-16) |
CL2018001213A CL2018001213A1 (es) | 2014-05-01 | 2018-05-04 | Composiciones de oligonocleótidos y métodos para realizarlas (divisional de sol. n°2749-16) |
Country Status (32)
Country | Link |
---|---|
US (5) | US9796747B2 (es) |
EP (2) | EP3137479B1 (es) |
JP (6) | JP7040892B2 (es) |
KR (2) | KR20230088509A (es) |
CN (3) | CN111228288B (es) |
AP (1) | AP2016009489A0 (es) |
AU (3) | AU2015253158B2 (es) |
BR (1) | BR112016025196B1 (es) |
CA (1) | CA2943888A1 (es) |
CL (4) | CL2016002749A1 (es) |
DK (1) | DK3137479T3 (es) |
EA (1) | EA034882B9 (es) |
ES (1) | ES2963740T3 (es) |
FI (1) | FI3137479T3 (es) |
HR (1) | HRP20231505T1 (es) |
HU (1) | HUE064289T2 (es) |
IL (2) | IL248044B (es) |
JO (2) | JOP20200257A1 (es) |
LT (1) | LT3137479T (es) |
MX (2) | MX2016014178A (es) |
MY (2) | MY178617A (es) |
PE (1) | PE20170147A1 (es) |
PH (1) | PH12016502080A1 (es) |
PL (1) | PL3137479T3 (es) |
PT (1) | PT3137479T (es) |
RS (1) | RS64860B1 (es) |
SG (2) | SG10201911086XA (es) |
SI (1) | SI3137479T1 (es) |
TW (2) | TWI712413B (es) |
UA (1) | UA126108C2 (es) |
WO (1) | WO2015168310A1 (es) |
ZA (2) | ZA201606624B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7485717B2 (en) * | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
JOP20200257A1 (ar) * | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
PT3286203T (pt) | 2015-04-23 | 2020-07-08 | Geron Corp | Métodos de preparação de polinucleótidos com a utilização de composições de sal de catiões multivalentes |
BR112020000410A2 (pt) * | 2017-07-10 | 2020-07-14 | Geron Corporation | processo aprimorado para preparar imetelstat |
US11530179B2 (en) * | 2019-10-28 | 2022-12-20 | Geron Corporation | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same |
AU2020375734A1 (en) | 2019-10-28 | 2022-05-26 | Geron Corporation | Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same |
WO2021141072A1 (ja) | 2020-01-08 | 2021-07-15 | 日東電工株式会社 | セグメント型アミダイトを用いた核酸合成法 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
JPH04503957A (ja) | 1989-03-07 | 1992-07-16 | ジェネンテク,インコーポレイテッド | 脂質とオリゴヌクレオチドの共有結合コンジュゲート |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
CA2079109A1 (en) | 1990-03-29 | 1991-09-30 | John A. Latham | Oligonucleotide-transport agent disulfide conjugates |
US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
US6087491A (en) | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
DE69434569T2 (de) | 1993-10-18 | 2006-08-24 | The Walter And Eliza Hall Institute Of Medical Research, Parkville | Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
AU704549B2 (en) | 1994-03-18 | 1999-04-29 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
WO1996001835A1 (en) | 1994-07-07 | 1996-01-25 | Geron Corporation | Mammalian telomerase |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
WO1996014277A1 (en) | 1994-11-07 | 1996-05-17 | Hybridon, Inc. | Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
AU2445997A (en) * | 1996-04-10 | 1997-10-29 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
CA2274586A1 (en) | 1996-12-20 | 1998-07-02 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
DK1210357T3 (da) | 1999-09-10 | 2008-07-21 | Geron Corp | Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf |
GB9927674D0 (en) * | 1999-11-23 | 2000-01-19 | Aegis Eng Ltd | Protective material |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
JP4854913B2 (ja) | 2001-03-23 | 2012-01-18 | ジェロン・コーポレーション | オリゴヌクレオチド結合体 |
AU2004271215B2 (en) | 2003-09-09 | 2009-07-16 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US20120329858A1 (en) * | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
US7427675B2 (en) * | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
AU2005295351A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
WO2006113470A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
ES2696828T3 (es) | 2006-10-30 | 2019-01-18 | Geron Corp | Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer |
WO2008094640A2 (en) * | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
US20150342982A1 (en) | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
-
2014
- 2014-05-01 JO JOP/2020/0257A patent/JOP20200257A1/ar unknown
-
2015
- 2015-04-29 FI FIEP15785822.6T patent/FI3137479T3/fi active
- 2015-04-29 CN CN202010050944.5A patent/CN111228288B/zh active Active
- 2015-04-29 HR HRP20231505TT patent/HRP20231505T1/hr unknown
- 2015-04-29 TW TW108147051A patent/TWI712413B/zh active
- 2015-04-29 ES ES15785822T patent/ES2963740T3/es active Active
- 2015-04-29 MY MYPI2016703971A patent/MY178617A/en unknown
- 2015-04-29 AP AP2016009489A patent/AP2016009489A0/en unknown
- 2015-04-29 SG SG10201911086XA patent/SG10201911086XA/en unknown
- 2015-04-29 RS RS20231110A patent/RS64860B1/sr unknown
- 2015-04-29 LT LTEPPCT/US2015/028327T patent/LT3137479T/lt unknown
- 2015-04-29 US US14/699,902 patent/US9796747B2/en active Active
- 2015-04-29 JP JP2016564990A patent/JP7040892B2/ja active Active
- 2015-04-29 PE PE2016002150A patent/PE20170147A1/es unknown
- 2015-04-29 EP EP15785822.6A patent/EP3137479B1/en active Active
- 2015-04-29 MY MYPI2020002421A patent/MY196927A/en unknown
- 2015-04-29 EP EP23193452.2A patent/EP4286519A3/en active Pending
- 2015-04-29 UA UAA201610381A patent/UA126108C2/uk unknown
- 2015-04-29 SG SG11201608226YA patent/SG11201608226YA/en unknown
- 2015-04-29 KR KR1020237018801A patent/KR20230088509A/ko not_active Application Discontinuation
- 2015-04-29 DK DK15785822.6T patent/DK3137479T3/da active
- 2015-04-29 CN CN201580022353.4A patent/CN106459134B/zh active Active
- 2015-04-29 TW TW104113709A patent/TWI709406B/zh active
- 2015-04-29 CA CA2943888A patent/CA2943888A1/en active Pending
- 2015-04-29 CN CN202311295220.7A patent/CN117357548A/zh active Pending
- 2015-04-29 PT PT157858226T patent/PT3137479T/pt unknown
- 2015-04-29 HU HUE15785822A patent/HUE064289T2/hu unknown
- 2015-04-29 PL PL15785822.6T patent/PL3137479T3/pl unknown
- 2015-04-29 BR BR112016025196-2A patent/BR112016025196B1/pt active IP Right Grant
- 2015-04-29 EA EA201691786A patent/EA034882B9/ru unknown
- 2015-04-29 WO PCT/US2015/028327 patent/WO2015168310A1/en active Application Filing
- 2015-04-29 SI SI201531963T patent/SI3137479T1/sl unknown
- 2015-04-29 KR KR1020167029996A patent/KR102316282B1/ko active IP Right Grant
- 2015-04-29 AU AU2015253158A patent/AU2015253158B2/en active Active
- 2015-04-29 JO JOP/2015/0089A patent/JO3767B1/ar active
- 2015-04-29 MX MX2016014178A patent/MX2016014178A/es unknown
-
2016
- 2016-09-23 ZA ZA2016/06624A patent/ZA201606624B/en unknown
- 2016-09-26 IL IL248044A patent/IL248044B/en active IP Right Grant
- 2016-10-19 PH PH12016502080A patent/PH12016502080A1/en unknown
- 2016-10-28 MX MX2021004932A patent/MX2021004932A/es unknown
- 2016-10-28 CL CL2016002749A patent/CL2016002749A1/es unknown
-
2017
- 2017-09-14 US US15/705,019 patent/US10392418B2/en active Active
- 2017-09-14 US US15/705,021 patent/US11299511B2/en active Active
-
2018
- 2018-05-01 JP JP2018088277A patent/JP2018131453A/ja active Pending
- 2018-05-04 CL CL2018001212A patent/CL2018001212A1/es unknown
- 2018-05-04 CL CL2018001213A patent/CL2018001213A1/es unknown
-
2019
- 2019-08-07 IL IL268570A patent/IL268570B/en unknown
- 2019-12-25 JP JP2019234301A patent/JP2020050670A/ja not_active Withdrawn
-
2020
- 2020-03-06 AU AU2020201707A patent/AU2020201707B2/en active Active
- 2020-09-22 ZA ZA2020/05857A patent/ZA202005857B/en unknown
-
2021
- 2021-09-06 JP JP2021144677A patent/JP2021182946A/ja active Pending
-
2022
- 2022-01-18 JP JP2022005584A patent/JP7308309B2/ja active Active
- 2022-01-26 CL CL2022000202A patent/CL2022000202A1/es unknown
- 2022-03-16 US US17/696,300 patent/US11739114B2/en active Active
- 2022-05-16 AU AU2022203273A patent/AU2022203273A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060170A patent/JP2023073510A/ja active Pending
- 2023-06-07 US US18/330,935 patent/US20240150391A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000202A1 (es) | Composiciones de oligonucleótidos y métodos para realizarlas (divisional de la solicitud no. 201602749) | |
ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
DK3577110T3 (da) | 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer | |
CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
DOP2016000253A (es) | Nuevos compuestos | |
ECSP11011391A (es) | Métodos y productos intermedios para preparar agentes farmacéuticos | |
AR100232A1 (es) | Detergente | |
CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
ES2561538T3 (es) | Composiciones que comprenden bacteriófagos líticos de Salmonella UAB_Phi20, UAB_Phi78 y UAB_ Phi87 y usos de los mismos | |
CO2018004581A2 (es) | Compuestos de criptoficina y productos conjugados, y sus métodos de preparación | |
UA42688S (uk) | Флакон для парфумерної продукції | |
MX2017015137A (es) | Composicion farmaceutica oral de dosis diaria de isotretinoin. | |
PA8781501A1 (es) | Formulacion de pasireotida | |
DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
EA201790321A1 (ru) | Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими | |
CL2017003082A1 (es) | Composiciones de caramelo cocido y productos alimenticios relacionados | |
CO2017004382A2 (es) | Composiciones farmacéuticas que comprenden lobeglitazona para administración oral | |
IL285487A (en) | New triterpene derivatives as hiv virus inhibitors | |
BR112017014235A2 (pt) | composição de grupo para a produção de um produto refratário, processo para a produção de um produto refratário, produto refratário e aplicação de um produto refratário. | |
GR20150100035A (el) | Φαρμακευτικο σκευασμα περιεχον απρεπιταντη και μεθοδος παρασκευης αυτου | |
BR112018008993A2 (pt) | entrega intratecal de sequências de ácidos nucleicos que codificam abcd1 para o tratamento de adrenomieloneuropatia |